Advaxis (ADXS) vs. Its Competitors Head to Head Survey

Advaxis (NASDAQ: ADXS) is one of 183 publicly-traded companies in the “Biotechnology & Medical Research” industry, but how does it weigh in compared to its competitors? We will compare Advaxis to similar companies based on the strength of its earnings, profitability, institutional ownership, dividends, risk, analyst recommendations and valuation.

Volatility and Risk

Advaxis has a beta of 1.96, meaning that its share price is 96% more volatile than the S&P 500. Comparatively, Advaxis’ competitors have a beta of 1.58, meaning that their average share price is 58% more volatile than the S&P 500.

Valuation and Earnings

This table compares Advaxis and its competitors top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Advaxis $3.99 million -$73.55 million -1.32
Advaxis Competitors $217.30 million -$39.39 million -72.24

Advaxis’ competitors have higher revenue and earnings than Advaxis. Advaxis is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.


This table compares Advaxis and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Advaxis -655.66% -93.54% -64.49%
Advaxis Competitors -3,096.84% -541.65% -37.93%

Institutional and Insider Ownership

41.4% of Advaxis shares are held by institutional investors. Comparatively, 48.1% of shares of all “Biotechnology & Medical Research” companies are held by institutional investors. 7.2% of Advaxis shares are held by company insiders. Comparatively, 14.5% of shares of all “Biotechnology & Medical Research” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Analyst Ratings

This is a summary of current recommendations and price targets for Advaxis and its competitors, as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Advaxis 0 0 2 0 3.00
Advaxis Competitors 526 2434 6525 124 2.65

Advaxis presently has a consensus target price of $21.00, indicating a potential upside of 593.07%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 14.00%. Given Advaxis’ stronger consensus rating and higher possible upside, equities research analysts plainly believe Advaxis is more favorable than its competitors.

Advaxis Company Profile

Advaxis, Inc. is a clinical-stage biotechnology company focused on the discovery, development and commercialization of Listeria monocytogenes (Lm)-Listeriolysin O (LLO) cancer immunotherapies. These immunotherapies are based on a platform technology that utilizes live attenuated Lm bioengineered to secrete antigen/adjuvant fusion proteins. These Lm-LLO strains integrate multiple functions into a single immunotherapy as they access and direct antigen presenting cells to stimulate anti-tumor T-cell immunity, stimulate and activate the immune system with the equivalent of multiple adjuvants, and simultaneously reduce tumor protection in the tumor microenvironment to enable the T-cells to eliminate tumors. Axalimogene filolisbac is its lead Lm-LLO immunotherapy product candidate for the treatment of Human Papilloma Virus-associated cancers. ADXS-PSA is its Lm-LLO immunotherapy product candidate that targets the Prostate Specific Antigen (PSA) associated with prostate cancer.

Receive News & Ratings for Advaxis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advaxis Inc. and related companies with's FREE daily email newsletter.

Leave a Reply